Login to Your Account



Give Biotechs Their Due [Diligence]

Learn Lessons Early to Avoid Those Nightmare Partnerships

By Mari Serebrov


Monday, March 28, 2011
Tekmira Pharmaceuticals Corp. filing a complaint alleging misappropriation of information and seeking potentially more than $1 billion in damages from RNAi partner Alnylam Pharmaceuticals Inc. might seem like a bad dream. After all, the horror stories of partnerships gone bad are the stuff of nightmares for biopharmaceutical companies looking for the right mate to advance a product.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription